Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic

Suzuki et al., medRxiv, doi:10.1101/2021.12.19.21268078 (Preprint)

Suzuki et al., Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate.., medRxiv, doi:10.1101/2021.12.19.21268078 (Preprint)

Dec 2021 Source PDF

Twitter
Facebook

All Studies Meta

Retrospective 949 patients in Japan, 314 treated with casirivimab/imdevimab showing significantly lower risk of deterioration with treatment.

Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron [Liu, Sheward, Tatham, VanBlargan].

1. Liu et al., bioRxiv, doi:10.1101/2021.12.14.472719, Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2, https://www.biorxiv.org/content/10.1101/2021.12.14.472719.

2. Sheward et al., bioRxiv, doi:10.1101/2021.12.19.473354, Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron), https://www.biorxiv.org/content/10.1101/2021.12.19.473354.

3. Tatham et al., bioRxiv, doi:10.1101/2022.01.23.477397, Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV 2 Omicron variant (B.1.1.529) in K18-hACE2 mice, https://www.biorxiv.org/content/10.1101/2022.01.23.477397.

4. VanBlargan et al., bioRxiv, doi:10.1101/2021.12.15.472828, An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies, https://www.biorxiv.org/content/10.1101/2021.12.15.472828v1.

Important missing comments or errors? Let us know.

risk of death, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 222 (0.5%), control 0 of 222 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), propensity score matching.

risk of death, 59.6% lower, RR 0.40, p = 0.67, treatment 1 of 314 (0.3%), control 5 of 635 (0.8%), NNT 213, unadjusted.

risk of progression, 45.2% lower, RR 0.55, p = 0.02, treatment 17 of 222 (7.7%), control 31 of 222 (14.0%), NNT 16, propensity score matching.

risk of progression, 49.9% lower, RR 0.50, p = 0.002, treatment 34 of 314 (10.8%), control 70 of 365 (19.2%), NNT 12, odds ratio converted to relative risk, multivariate.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Suzuki et al., 21 Dec 2021, retrospective, Japan, preprint, 49 authors, study period 24 July, 2021 - 30 September, 2021.

Contact: shibatay@fmu.ac.jp.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Casirivimab/i..All

Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic

Yasuhito Suzuki, MD Yoko Shibata, Hiroyuki Minemura, Takefumi Nikaido, Yoshinori Tanino, Atsuro Fukuhara, Ryuzo Kanno, Hiroyuki Saito, Shuzo Suzuki, Taeko Ishii, Yayoi Inokoshi, Eiichiro Sando, Hirofumi Sakuma, Tatsuho Kobayashi, Hiroaki Kume, Masahiro Kamimoto, Hideko Aoki, Akira Takama, Takamichi Kamiyama, Masaru Nakayama, Kiyoshi Saito, Koichi Tanigawa, Masahiko Sato, Toshiyuki Kanbe, Norio Kanzaki, Teruhisa Azuma, Keiji Sakamoto, Yuichi Nakamura, Hiroshi Otani, Mitsuru Waragai, Shinsaku Maeda, Tokiya Ishida, Keishi Sugino, Yasuhiko Tsukada, Ryuki Yamada, Riko Sato, Takumi Omuna, Hikaru Tomita, Mikako Saito, Natsumi Watanabe, Mami Rikimaru, Takaya Kawamata, Takashi Umeda, Julia Morimoto, Ryuichi Togawa, Yuki Sato, Junpei Saito, Kenya Kanazawa, Ken Iseki

doi:10.1101/2021.12.19.21268078

This real-world retrospective study demonstrates the contribution of treatment with casirivimab-imdevimab to the prevention of deterioration in patients with mild-to-All rights reserved. No reuse allowed without permission. perpetuity.

References

Abu-Raddad, Chemaitelly, Butt, Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants, The New England journal of medicine

Austin, Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies, Pharmaceutical statistics

Baum, Fulton, Wloga, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, Science

Bernal, Andrews, Gower, Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant, The New England journal of medicine

Ganesh, Philpot, Bierle, Real-World Clinical Outcomes of Bamlanivimab and Casirivimab-Imdevimab Among High-Risk Patients With Mild to Moderate Coronavirus Disease 2019, The Journal of infectious diseases

Gottlieb, Nirula, Chen, Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, Jama

Hu, Peng, Wang, Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies, Cellular & molecular immunology

Huang, Yang, Xu, Xu, Liu, Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19, Acta pharmacologica Sinica

Ito, Piantham, Nishiura, Predicted dominance of variant Delta of SARS-CoV-2 before Tokyo Olympic Games, Japan, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Korber, Fischer, Gnanakaran, Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus, Cell

Kumar, Banu, Sasikala, Effectiveness of REGEN-COV antibody cocktail against the B.1.617.2 (delta) variant of SARS-CoV-2: A cohort study, Journal of internal medicine

Planas, Veyer, Baidaliuk, Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization, Nature

Polack, Thomas, Kitchin, Safety and Efficacy of the BNT162b2 mRNA Covid-19

Razonable, Pawlowski, Horo, Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19, EClinicalMedicine

Shiba, Kawahara, Using Propensity Scores for Causal Inference: Pitfalls and Tips, Journal of epidemiology

Shibata, Minemura, Suzuki, Development and external validation of the DOAT and DOATS scores: simple decision support tools to identify disease progression among nonelderly patients with mild/moderate COVID-19

Taylor, Adams, Hufford, De La Torre, Winthrop et al., Neutralizing monoclonal antibodies for treatment of COVID-19, Nature reviews Immunology

The_Official_Website_Of_Fukushima_Prefecture, Confirmed cases of COVID-19 in Fukushima

The_Official_Website_Of_Fukushima_Prefecture, The variant of COVID-19 in Fukushima from

Uriu, Kimura, Shirakawa, Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum, The New England journal of medicine

Vaccine, None, The New England journal of medicine

Verderese, Stepanova, Lam, Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience, Clinical infectious diseases

Wang, Nair, Liu, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, Nature

Weinreich, Sivapalasingam, Norton, REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19, The New England journal of medicine

Wilhelm, Toptan, Pallas, Antibody-Mediated Neutralization of Authentic SARS-CoV

Yamamoto, Wada, Ichikawa, Evaluation of Biomarkers of Severity in Patients with COVID-19 Infection, J Clin Med

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit